Connect to other sites within the UBM Medica Network
Pazopanib/Paclitaxel Combo Active in Refractory, Relapsed Urothelial Carcinoma
Phase II study results found that half of patients with relapsed or refractory urothelial carcinoma responded to treatment with pazopanib and paclitaxel.
New Era of Bladder Cancer Treatments Has Begun
In this interview we discuss the changing landscape of systemic therapies for the treatment of bladder cancer.
Adjuvant Chemotherapy Improves Survival in Bladder Cancer
Patients with bladder cancer derived an overall survival benefit from the use of adjuvant chemotherapy compared with observation.
Urine Test Detects Bladder Cancer Recurrence
A urine test (CellDetect) was able to detect disease recurrence in bladder cancer patients, with a reported sensitivity of 84.4% and specificity of 82.7%.
Bladder Cancer: Mortality, Morbidity, and QoL After Treatment
While observation may be appropriate for select cases where prognosis is poor, rates of non-treatment are unacceptably high in muscle-invasive bladder cancer.
Bladder Cancer Survival Similar With Laparoscopic, Open Surgery
Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.
Million-Person Study Shows No Link Between Pioglitazone and Bladder Cancer
An extremely large database study across more than one million people found no increased risk of bladder cancer with the diabetes drug pioglitazone.
By clicking Accept, you agree to become a member of the UBM Medica Community.